Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Infection and Immunity|May 2, 2007
Leishmania major abrogates gamma interferon-induced gene expression in human macrophages from a global perspectiveNisha Dogra, Corinna Warburton, W Robert McMaster
Drug Development and Industrial Pharmacy|October 27, 2007
Treatment with a cholesterol absorption inhibitor (FM-VP4) reduces body mass and adipose accumulation in developing and pre-obese miceSheila J Thornton, Corinna Warburton, Kishor M Wasan, et al.
Vaccine|January 5, 2005
Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trialsNoushin Davoudi, Celia A Tate, Corinna Warburton, et al.
Plos One|April 5, 2013
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor modelMaite Verreault, Sherry A Weppler, Amelia Stegeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fractionCorinna Warburton, Wieslawa H Dragowska, Karen Gelmon, et al.
Cancer Biology & Therapy|March 2, 2011
Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267Jessica Kalra, Malathi Anantha, Corinna Warburton, et al.
Breast Cancer Research : BCR|May 5, 2009
QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer modelJessica Kalra, Corinna Warburton, Karen Fang, et al.
Breast Cancer Research and Treatment|March 10, 2007
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycinWieslawa H Dragowska, Maïté Verreault, Donald T T Yapp, et al.
Oncotarget|July 30, 2015
3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agentsAda W Y Leung, Wieslawa H Dragowska, Daniel Ricaurte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2017
In Vivo Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic TargetAda W Y Leung, Chansey J Veinotte, Nicole Melong, et al.
Pageof 2